»ù±¾ÐÅÏ¢
²úÆ·Æ·ÅÆ £º½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual MeetingÉúÎï
ÖÐÎÄÃû³Æ £ºÈËÈéÏÙ°©Ï¸°û(ÂÌɫӫ¹âµ°°×±ê¼Ç)
ϸ°û¼ò³Æ £ºMDA-MB-231
ϸ°û±ð³Æ £ºMDA-MB 231; MDA.MB.231; MDA MB 231; MDA MB231; MDA Mb231;MDA-MB231; MDAMB-231; MDAMB231; MDA-231; MDA231; MB231;MD Anderson-Metastatic Breast-231
ϸ°ûÐÎ̬ £ºÉÏÆ¤Ï¸°ûÑù
Éú³¤ÌØÐÔ £ºÌù±Úϸ°û
ÅàÑø»·¾³ £º¿ÕÆø£¬100% 37¡æ
¶³´æÌõ¼þ £º55% »ù´¡ÅàÑø»ù+40%FBS+5%DMSOÒºµª
ÍêÈ«ÅàÑø»ù £ºLeibovitz's L-15(PM151010)£«10% FBS(164210-50)£«1% P/S(PB180120)
´«´ú²½Öè
1¡¢Îü³öÔÅàÑøÒº¡£
2¡¢¼ÓÈë2ml×óÓÒPBS£¬ÇáÇá»Î¶¯ÅàÑøÆ¿Èóϴϸ°û,Îü³öPBS¶ªÆú¡£
3¡¢¼ÓÈë1ml×óÓÒ0.25%Òȵ°°×øÈÜÒº£¨º¬EDTA£©£¬ÇáÇá»Î¶¯ÅàÑøÆ¿Ê¹Ö®½þÈóËùÓÐϸ°û¡£
4¡¢·ÅÈëÅàÑøÏäÏû»¯£¬ÏÔ΢¾µÏ¿´µ½Ï¸°û¿éÖмäµÄϸ°ûÃ÷ÏÔ±äÔ²Óмä϶ʱ¿ÉÖÕÖ¹£¬È«³Ì²»ÒªÅÄ´òÅàÑøÆ¿¡£
5¡¢¼ÓÈë3mlº¬ÑªÇåµÄÅàÑø»ùÖÕÖ¹Ïû»¯£¬´µ´òϸ°ûʹ֮Íѱڲ¢ÔÚÒºÌåÀï·´¸´´µ´òʹϸ°û¾¡Á¿³Êµ¥¿Åϸ°ûµÄÐü¸¡Òº¡£
6¡¢ÊÕ¼¯Ï¸°ûÐüÒºÀëÐÄ£¬1200rpm/min 3·ÖÖÓ£¬ÀëÐÄÍêÎü³öÉÏÇ嶪Æú¡£
7¡¢¼ÓÈëÐÂÏÊÅàÑø»ù£¬´µ´ò¼¸Ï»ìÔÈϸ°û¼´¿É£¬°´±ÈÀý½ÓÖÖµ½ÐÂÅàÑøÆ¿£¬²¹×ãÅàÑø»ù£¬Å¡ËÉÆ¿¸Ç»òʹÓÃÍ¸ÆøÆ¿¸Ç½øÐÐÅàÑø¡£
Ïû»¯Ê±¼ä £º2-3min
´«´ú±ÈÀý£¨Ãܶȣ© £º1:2-1:4
»»ÒºÆµ´Î £º2~3´Î/ÖÜ
ϸ°û±³¾°ÃèÊö
MDA-MB-231À´×Ô»¼ÓÐ×ªÒÆÈéÏÙÏÙ°©µÄ51ËêÅ®²¡È˵ÄÐØË®¡£ ÔÚÂãÊóºÍALS´¦ÀíµÄBALB/cСÊóÖУ¬ËüÄÜÐγɵͷֻ¯ÏÙ°©£¨III¼¶£©¡£Ï¸°û±í´ïWNT7B°©»ùÒò¡£
±¶Ôöʱ¼ä £º~32-42Сʱ
¹©ÌåÄêÁä £ºÅ®ÐÔ£¬51Ëê
×éÖ¯À´Ô´ £ºÈéÏÙÏÙ°©£¬×ªÒÆÐÔÐØÄ¤Éø³öÒº
ϸ°ûÀàÐÍ £ºÖ×Áöϸ°û
Ö×ÁöÀàÐÍ £ºÈéÏÙ°©Ï¸°û
ÉúÎﰲȫµÈ¼¶ £º1
ÖÂÁöÐÔ £ºYes, in ALS treated BALB/c mice, forms poorly differentiatedadenocarcinoma (grade III).Yes, in nude mice, forms poorly differentiatedadenocarcinoma (grade III)¡£
ÊÜÌå±í´ï £ºepidermal growth factor (EGF), expressed;transforming growth factor alpha(TGF alpha), expressed
ϸ°û±£²ØÖÐÐÄ £ºATCC; CRL-12532ATCC; HTB-26 ATCC; CRM-HTB-26 BCRC; 60425BCRJ; 0164 DSMZ; ACC-732 ECACC; 92020424
ÊÕµ½³£ÎÂϸ°ûºóÈçºÎ´¦Àí
ϸ°ûÅàÑøÏêϸ²Ù×÷²½ÖèÇë²ÎÕÕ½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual MeetingÉúÎïϸ°ûÅàÑø²Ù×÷Ö¸ÄÏ
1.ÊÕµ½³£ÎÂϸ°ûºó£¬¼°Ê±ÅÄÕռǼÓÐÎÞ©Һ/Æ¿ÉíÆÆËðÏÖÏó¡£
2.ÓÃ75%¾Æ¾«²ÁÊÃϸ°ûÅàÑøÆ¿±íÃæ£¬ÏÔ΢¾µÏ¹۲ìϸ°û״̬¡£ÏȲ»Òª´ò¿ªÅàÑøÆ¿¸Ç£¬½«Ï¸°ûÖÃÓÚϸ°ûÅàÑøÏäÄÚ¾²ÖÃÅàÑø2-4Сʱ£¬ÒÔ±ãÎȶ¨Ï¸°û״̬¡£
3.×ÐϸÔĶÁϸ°û˵Ã÷Ê飬Á˽âϸ°ûÏà¹ØÐÅÏ¢£¬ÈçÌù±ÚÌØÐÔ£¨Ìù±Ú/Ðü¸¡£©¡¢Ï¸°ûÐÎ̬¡¢ËùÓûù´¡ÅàÑø»ù¡¢ÑªÇå±ÈÀý¡¢ËùÐèϸ°ûÒò×Ó¡¢´«´ú±ÈÀý¡¢»»ÒºÆµÂʵȡ£
4.¾²ÖÃÍê³Éºó£¬È¡³öϸ°ûÅàÑøÆ¿£¬¾µ¼ì¡¢ÅÄÕÕ£¬¼Ç¼ϸ°û״̬£¨ËùÅÄÕÕÆ¬ ½«×÷ΪºóÐø·þÎñÒÀ¾Ý£©£»½¨Òéϸ°û´«´úÅàÑøºó£¬¶¨ÆÚÅÄÕÕ¡¢¼Ç¼ϸ°ûÉú³¤×´Ì¬¡£
5.Èô¹Û²ìµ½Òì³£»òÕß¶Ôϸ°ûÓÐÒÉÎÊ£¬Ç뼰ʱ¸úÎÒÃÇÁªÏµ£»¶ÔÓÚϸ°ûÅàÑø²Ù×÷¼°ÅàÑø¡£¿É¸úÎÒÃǵļ¼ÊõÖ§³Ö½»Á÷¡£
ÊÛǰÐëÖª
1¡¢¸Ãϸ°ûÍÆ¼öʹÓÃLeibovitz's L-15ÅàÑø»ù½øÐÐÅàÑø£¬Leibovitz's L-15²»¿ÉÒÔͨÈë¶þÑõ»¯Ì¼£¬»á²úÉúϸ°û¶¾ÐÔ¡£
2¡¢ÈçÄúûÓÐÎÞ¶þÑõ»¯Ì¼µÄÅàÑøÏ䣬¿ÉʹÓÃDMEMÌæ´úLeibovitz's L-15£¬Ê¹ÓÃDMEMÅàÑø»ùʱ¼´¿ÉÕý³£Í¨Èë5%¶þÑõ»¯Ì¼¡£
3¡¢ÅäÌ×רÓÃÅàÑø»ùĬÈÏLeibovitz's L-15ÅäÖã¬ÈçÐèDMEMÅä·½£¬ÇëÁªÏµÏúÊÛϵ¥±¸×¢¸ü¸Ä¡£